Answers are grounded in this paper and cite their sources.
A 69-y-old treatment-naïve man with biopsy-confirmed small cell lung cancer (SCLC) was enrolled in an ongoing phase 1/2 study targeting Delta-like ligand 3 (DLL3) with 68Ga-PFD3 PET/CT for the diagnosis and assessment of SCLC ([NCT07508852][1]). 18F-FDG and 68Ga-PFD3 PET/CT were performed 72 h
No takes yet. Share an insight, caveat, or question.
Lei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: